Isli Cela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Isli Cela has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Larysa Baraban
Institute of Radiopharmaceutical Cancer Research Helmholtz‐Zentrum Dresden‐Rossendorf Dresden Germany
2 shared publications - Abbas Guven Akcay
Department of Molecular Biology and Genetics, Bilkent University, Ankara 06800, Turkey
1 shared publication - Ahmed Alsadig
Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 01328 Dresden, Germany
1 shared publication - Ali Osmay Gure
Skopos Global Ltd., Atasehir, Istanbul 34750, Turkey
1 shared publication - Andreas Fery
Leibniz Institute of Polymer Research
1 shared publication - Anja Feldmann
Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany
1 shared publication
Latest Publications
- Open Access
- 7 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Enhanced Refractive Index Sensitivity of LinearlyAssembled Gold Nanoantennae for BiosensingApplications
Near-field interactions between individual gold nanoparticles (AuNPs) in clusters or arrays open a new avenue for highly sensitive plasmonic biosensors, owing to their significant impact on the localized surface plasmon resonance. Compared to individual nanoparticles, supracolloidal structures offer unique plasmonic properties with the enhanced susceptibilities to variations in the local refractive index. In this study, we report on the template-assisted fabrication of large-scale (ca. 1 cm²) linear periodic assemblies of AuNPs and demonstrate their polarization dependent biosensing performance at the proof-of concept level. We explored two complementary approaches for template fabrication: (i) laser interference lithography (LIL), offering high-fidelity patterns over moderate areas, and (ii) wrinkle-assisted patterning, a more scalable and costeffective strategy. Despite structural differences, both approaches yielded comparable high biosensing performances, demonstrating broad potential utility of the developed biosensing platform. As a proof-of-concept application, we performed biofunctionalization and detection of the antibody for Tumor Necrosis Factor-Alpha (TNF-α), a pro-inflammatory cytokine that plays a multifaceted role in cancer prognosis. The shifts in plasmonic resonance peaks of the AuNP assemblies were quantified using polarized-light vis-NIR spectrometry during various stages of the functionalization and detection process. The experimental results revealed a pronounced polarization-dependent plasmonic resonance peak shift (Δλ), with up to a 5-fold increase observed in the longitudinal mode over the transversal case, a feature consistently achieved across both LIL 3 and wrinkled templates. These findings present an innovative supracolloidal structuring approach for the development and scalable production of highly sensitive, plasmonic biochips.
- 7 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessEnhanced Refractive Index Sensitivity of LinearlyAssembled Gold Nanoantennae for BiosensingApplications
Near-field interactions between individual gold nanoparticles (AuNPs) in clusters or arrays open a new avenue for highly sensitive plasmonic biosensors, owing to their significant impact on the localized surface plasmon resonance. Compared to individual nanoparticles, supracolloidal structures offer unique plasmonic properties with the enhanced susceptibilities to variations in the local refractive index. In this study, we report on the template-assisted fabrication of large-scale (ca. 1 cm²) linear periodic assemblies of AuNPs and demonstrate their polarization dependent biosensing performance at the proof-of concept level. We explored two complementary approaches for template fabrication: (i) laser interference lithography (LIL), offering high-fidelity patterns over moderate areas, and (ii) wrinkle-assisted patterning, a more scalable and costeffective strategy. Despite structural differences, both approaches yielded comparable high biosensing performances, demonstrating broad potential utility of the developed biosensing platform. As a proof-of-concept application, we performed biofunctionalization and detection of the antibody for Tumor Necrosis Factor-Alpha (TNF-α), a pro-inflammatory cytokine that plays a multifaceted role in cancer prognosis. The shifts in plasmonic resonance peaks of the AuNP assemblies were quantified using polarized-light vis-NIR spectrometry during various stages of the functionalization and detection process. The experimental results revealed a pronounced polarization-dependent plasmonic resonance peak shift (Δλ), with up to a 5-fold increase observed in the longitudinal mode over the transversal case, a feature consistently achieved across both LIL 3 and wrinkled templates. These findings present an innovative supracolloidal structuring approach for the development and scalable production of highly sensitive, plasmonic biochips.
- Open Access
- 7 August 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Towards Precision CAR T-cell Immunotherapy: extended gate FET biosensor for personalized drug monitoring
Selection and optimization of therapies for cancer patients urgently needs personalization. Portable point-of-care electronic biosensors emerge as a groundbreaking solution to contribute to better decision-making in precision oncology. This study showcases the innovative use of extended gate field-effect transistor (EG-FET) biosensors to monitor the concentration and pharmacokinetics of immunotherapeutic drugs in vivo. Complementary positron emission tomography (PET) and radioactivity biodistribution studies in mice validate the EG-FET measurements. We introduce a novel indirect assay format for detecting target modules in an adapter CAR T-cell therapy model, effectively addressing the limitations of traditional potentiometric measurements. The EG-FET sensors exhibit exceptional sensitivity, and fulfill the requirements for immunotherapeutic drug monitoring without the need for complex radioactive labeling. In pharmacokinetic evaluations, the FET-based biosensor's performance aligns with standard radioactive measurements, revealing the distinct lifespans of small-sized TMs (15 minutes for scFv type) and larger TMs (14 hours for IgG4 type). These promising findings advocate for further exploration of next-generation biosensors in therapeutic monitoring roles. With their cost, size, and response time advantages, these biosensors hold immense potential for advancing personalized oncology, transcending the conventional diagnostic roles typically highlighted in the literature.
- 7 August 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessTowards Precision CAR T-cell Immunotherapy: extended gate FET biosensor for personalized drug monitoring
Selection and optimization of therapies for cancer patients urgently needs personalization. Portable point-of-care electronic biosensors emerge as a groundbreaking solution to contribute to better decision-making in precision oncology. This study showcases the innovative use of extended gate field-effect transistor (EG-FET) biosensors to monitor the concentration and pharmacokinetics of immunotherapeutic drugs in vivo. Complementary positron emission tomography (PET) and radioactivity biodistribution studies in mice validate the EG-FET measurements. We introduce a novel indirect assay format for detecting target modules in an adapter CAR T-cell therapy model, effectively addressing the limitations of traditional potentiometric measurements. The EG-FET sensors exhibit exceptional sensitivity, and fulfill the requirements for immunotherapeutic drug monitoring without the need for complex radioactive labeling. In pharmacokinetic evaluations, the FET-based biosensor's performance aligns with standard radioactive measurements, revealing the distinct lifespans of small-sized TMs (15 minutes for scFv type) and larger TMs (14 hours for IgG4 type). These promising findings advocate for further exploration of next-generation biosensors in therapeutic monitoring roles. With their cost, size, and response time advantages, these biosensors hold immense potential for advancing personalized oncology, transcending the conventional diagnostic roles typically highlighted in the literature.
- Open Access
- 31 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 6054
Breast Cancer Plasticity after Chemotherapy Highlights the Need for Re-Evaluation of Subtyping in Residual Cancer and Metastatic Tissues
This research paper presents a novel approach to identifying biomarkers that can be used to prognosticate patients with triple-negative breast cancer (TNBC) eligible for neoadjuvant therapy. The study utilized survival and RNA sequencing data from a cohort of TNBC patients and identified 276 genes whose expression was related to survival in such patients. The gene expression data were then used to classify patients into two major groups based on the presence or absence of Wingless/Integrated-pathway (Wnt-pathway) and mesenchymal (Mes) markers (Wnt/Mes). Patients with a low expression of Wnt/Mes-related genes had a favorable outcome, with no deaths observed during follow-up, while patients with a high expression of Wnt/Mes genes had a higher mortality rate of 50% within 19 months. The identified gene list could be validated and potentially used to shape treatment options for TNBC patients eligible for neoadjuvant therapy providing valuable insights into the development of more effective treatments for TNBC. Our data also showed significant variation in gene expression profiles before and after chemotherapy, with most tumors switching to a more mesenchymal/stem cell-like profile. To verify this observation, we performed an in silico analysis to classify breast cancer tumors in Prediction Analysis of Microarray 50 (PAM50) molecular classes before treatment and after treatment using gene expression data. Our findings demonstrate that following drug intervention and metastasis, certain tumors undergo a transition to alternative subtypes, resulting in diminished therapeutic efficacy. This underscores the necessity for reevaluation of patients who have experienced relapse or metastasis post-chemotherapy, with a focus on molecular subtyping. Tailoring treatment strategies based on these refined subtypes is imperative to optimize therapeutic outcomes for affected individuals.
- 31 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 6054
Open AccessBreast Cancer Plasticity after Chemotherapy Highlights the Need for Re-Evaluation of Subtyping in Residual Cancer and Metastatic Tissues
This research paper presents a novel approach to identifying biomarkers that can be used to prognosticate patients with triple-negative breast cancer (TNBC) eligible for neoadjuvant therapy. The study utilized survival and RNA sequencing data from a cohort of TNBC patients and identified 276 genes whose expression was related to survival in such patients. The gene expression data were then used to classify patients into two major groups based on the presence or absence of Wingless/Integrated-pathway (Wnt-pathway) and mesenchymal (Mes) markers (Wnt/Mes). Patients with a low expression of Wnt/Mes-related genes had a favorable outcome, with no deaths observed during follow-up, while patients with a high expression of Wnt/Mes genes had a higher mortality rate of 50% within 19 months. The identified gene list could be validated and potentially used to shape treatment options for TNBC patients eligible for neoadjuvant therapy providing valuable insights into the development of more effective treatments for TNBC. Our data also showed significant variation in gene expression profiles before and after chemotherapy, with most tumors switching to a more mesenchymal/stem cell-like profile. To verify this observation, we performed an in silico analysis to classify breast cancer tumors in Prediction Analysis of Microarray 50 (PAM50) molecular classes before treatment and after treatment using gene expression data. Our findings demonstrate that following drug intervention and metastasis, certain tumors undergo a transition to alternative subtypes, resulting in diminished therapeutic efficacy. This underscores the necessity for reevaluation of patients who have experienced relapse or metastasis post-chemotherapy, with a focus on molecular subtyping. Tailoring treatment strategies based on these refined subtypes is imperative to optimize therapeutic outcomes for affected individuals.